Management of Bleeding Complications in the Anticoagulated Patient

Seminars in Hematology

Volumn 48, Issue 4, 2011, Pages 285-294

  Bhagirath, Vinai C ^a   O'Malley, Lauren ^a   Crowther, Mark A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; ARGIPRESSIN[1 DEAMINO]; AVIDIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; FONDAPARINUX; FRESH FROZEN PLASMA; HEPARIN; HEPARIN BINDING PEPTIDE; HIRUDIN; HIRULOG; IDRABIOTAPARINUX; IDRAPARINUX; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; PEPTIDE; PROTAMINE SULFATE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT THROMBOCYTE FACTOR 4; RICINOMACROGOL; RIVAROXABAN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN;

ABSENCE OF SIDE EFFECTS; ANAPHYLAXIS; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CRYOPRECIPITATE; CYTOPENIA; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; FLUSHING; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPOTENSION; LUNG VASOCONSTRICTION; NAUSEA; NONHUMAN; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; STROKE; THROMBOEMBOLISM; THROMBOSIS; URTICARIA; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEMORRHAGE; HUMANS; VITAMIN K; WARFARIN;

EID: 80053956337     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2011.08.008     Document Type: Article

References (139)

1. Schulman S., Beyth R.J., Kearon C., Levine M.N. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133(6 Suppl):257S-298S. American College of Chest Physicians.
2. Ansell J., Hirsh J., Hylek E., et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133(6 Suppl):160S-198S.
3. Kaufman D.W., Kelly J.P., Rosenberg L., Anderson T.E., Mitchell A.A. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002, 287:337-344.
4. Fitzmaurice D.A., Blann A.D., Lip G.Y. Bleeding risks of antithrombotic therapy. BMJ 2002, 325:828-831.
5. Dentali F., Crowther M.A. Management of excessive anticoagulant effect due to vitamin K antagonists. Hematol Am Soc Hematol Educ Program 2008, 266-270.
6. Landefeld C.S., Rosenblatt M.W., Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med 1989, 87:153-159.
7. Hylek E.M., Chang Y.C., Skates S.J., Hughes R.A., Singer D.E. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000, 160:1612-1617.
8. Nee R., Doppenschmidt D., Donovan D.J., Andrews T.C. Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am J Cardiol 1999, 83:286-288.
9. Raj G., Kumar R., McKinney W.P. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med 1999, 159:2721-2724.
10. Lubetsky A., Yonath H., Olchovsky D., Loebstein R., Halkin H., Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003, 163:2469-2473.
11. Crowther M.A., Douketis J.D., Schnurr T., et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002, 137:251-254.
12. Hung A., Singh S., Tait R.C. A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization. Br J Haematol 2000, 109:537-539.
13. Riegert-Johnson D.L., Volcheck G.W. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann Allergy Asthma Immunol 2002, 89:400-406.
14. Makris M., Watson H.G. The management of coumarin-induced over-anticoagulation. Br J Haematol 2001, 114:271-280.
15. Makris M., Greaves M., Phillips W.S., Kitchen S., Rosendaal F.R., Preston E.F. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997, 77:477-480.
16. Lee S.B., Manno E.M., Layton K.F., Wijdicks E.F. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology 2006, 67:1272-1274.
17. Baglin T.P., Keeling D.M., Watson H.G. Guidelines on oral anticoagulation (warfarin): third edition-2005 update. Br J Haematol 2006, 132:277-285. British Committee for Standards in Haematology.
18. Boulis N.M., Bobek M.P., Schmaier A., Hoff J.T. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999, 45:1113-1118.
19. Crosby E., Ferguson D., Hume H.A., Kronick J.B., Larke B. Guidelines for red blood cell and plasma transfusion for adults and children. CMAJ 1997, 156(11 Suppl):S1.
20. Evans G., Luddington R., Baglin T. Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol 2001, 115:998-1001.
21. Preston F.E., Laidlaw S.T., Sampson B., Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol 2002, 116:619-624.
22. Lubetsky A., Hoffman R., Zimlichman R., et al. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res 2004, 113:371-378.
23. Lankiewicz M.W., Hays J., Friedman K.D., Tinkoff G., Blatt P.M. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006, 4:967-970.
24. Nitu I.C., Perry D.J., Lee C.A. Clinical experience with the use of clotting factor concentrates in oral anticoagulation reversal. Clin Lab Haematol 1998, 20:363-367.
25. Crawford J.H., Augustson B.M. Prothrombinex use for the reversal of warfarin: is fresh frozen plasma needed?. Med J Aust 2006, 184:365-366.
26. Pabinger I., Brenner B., Kalina U., et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008, 6:622-631.
27. Vigue B., Ract C., Tremey B., et al. Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med 2007, 33:721-725.
28. Cartmill M., Dolan G., Byrne J.L., Byrne P.O. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000, 14:458-461.
29. Fredriksson K., Norrving B., Stromblad L.G. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992, 23:972-977.
30. van Aart L., Eijkhout H.W., Kamphuis J.S., et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res 2006, 118:313-320.
31. Yasaka M., Sakata T., Minematsu K., Naritomi H. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res 2002, 108:25-30.
32. Baker R.I., Coughlin P.B., Gallus A.S., et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004, 181:492-497.
33. Holland L., Warkentin T.E., Refaai M., Crowther M.A., Johnston M.A., Sarode R. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion 2009, 49:1171-1177.
34. Imberti D., Barillari G., Biasioli C., et al. Emergency reversal of anticoagulation with a three-factor prothrombin complex concentrate in patients with intracranial haemorrhage. Blood Transfus 2011, 9:148-155.
35. Tran H., Collecutt M., Whitehead S., Salem H.H. Prothrombin complex concentrates used alone in urgent reversal of warfarin anticoagulation. Intern Med J 2011, 41:337-343.
36. Makris M., Van Veen J.J. Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal?. Blood Transfus 2011, 9:117-119.
37. Pernod G., Godier A., Gozalo C., Tremey B., Sie P. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thromb Res 2010, 126:e167-e174.
38. Sorensen B., Johansen P., Nielsen G.L., Sorensen J.C., Ingerslev J. Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003, 14:469-477.
39. Freeman W.D., Brott T.G., Barrett K.M., et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004, 79:1495-1500.
40. Lin J., Hanigan W.C., Tarantino M., Wang J. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg 2003, 98:737-740.
41. Brody D.L., Aiyagari V., Shackleford A.M., Diringer M.N. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2005, 2:263-267.
42. Dager W.E., King J.H., Regalia R.C., et al. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy 2006, 26:1091-1098.
43. Deveras R.A., Kessler C. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002, 137:884-888.
44. Rosovsky R.P., Crowther M.A. What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin?. ASH evidence-based review 2008. Hematol Am Soc Hematol Educ Program 2008, 36-38.
45. Hirsh J., Bauer K.A., Donati M.B., et al. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133(6 Suppl):141S-159S.
46. Kearon C., Ginsberg J.S., Julian J.A., et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006, 296:935-942.
47. Fernandez F., N'guyen P., Van Ryn J., Ofosu F.A., Hirsh J., Buchanan M.R. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 1986, 43:491-495.
48. Morabia A. Heparin doses and major bleedings. Lancet 1986, 1:1278-1279.
49. Antman E.M. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994, 90:1624-1630.
50. Antman E.M. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996, 94:911-921.
51. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994, 330:956-961. The EPIC Investigation.
52. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994, 90:1631-1637. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators.
53. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996, 335:775-782. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators.
54. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997, 336:1689-1696. The EPILOG Investigators.
55. Crowther M.A., Berry L.R., Monagle P.T., Chan A.K. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 2002, 116:178-186.
56. Dolovich L.R., Ginsberg J.S., Douketis J.D., Holbrook A.M., Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000, 160:181-188.
57. Gould M.K., Dembitzer A.D., Doyle R.L., Hastie T.J., Garber A.M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999, 130:800-809.
58. van Dongen C.J., van den Belt A.G., Prins M.H., Lensing A.W. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004, 4. CD001100.
59. Blazing M.A., de Lemos J.A., White H.D., et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004, 292:55-64.
60. Ferguson J.J., Califf R.M., Antman E.M., et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004, 292:45-54.
61. van Veen J.J., Laidlaw S., Maclean R.M., Hampton K.K., Makris M. Clinical use of protamine for the emergency reversal of anticoagulation with low molecular weight heparin (LMWH). J Thromb Haemost 2005, 3(Suppl 1):P2049.
62. Patel A.A., White C.M., Coleman C.I. Use of protamine to rapidly reverse anticoagulant effect of unfractionated heparin in patients undergoing percutaneous coronary intervention. Conn Med 2007, 71:93-95.
63. Crowther M.A., Warkentin T.E. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008, 111:4871-4879.
64. Warkentin T.E., Crowther M.A. Reversing anticoagulants both old and new. Can J Anaesth 2002, 49:S11-S25.
65. Crowther M.A., Warkentin T.E. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008, 111:4871-4879.
66. Caplan S.N., Berkman E.M. Protamine sulfate and fish allergy. N Engl J Med 1976, 295:172. (letter).
67. Nybo M., Madsen J.S. Serious anaphylactic reactions due to protamine sulfate: a systematic literature review. Basic Clin Pharmacol Toxicol 2008, 103:192-196.
68. Park K.W. Protamine and protamine reactions. Int Anesthesiol Clin 2004, 42:135-145.
69. Weiler J.M., Gellhaus M.A., Carter J.G., et al. A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery. J Allergy Clin Immunol 1990, 85:713-719.
70. Weiss M.E., Nyhan D., Peng Z.Z.K., et al. Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. N Engl J Med 1989, 320:886-892.
71. Weiss M.E., Adkinson N.F. Allergy to protamine. Clin Rev Allergy 1991, 9:339-355.
72. Mixon T.A., Dehmer G.J. Recombinant platelet factor 4 for heparin neutralization. Semin Thromb Hemost 2004, 30:369-377.
73. Stewart W.J., McSweeney S.M., Kellett M.A., Faxon D.P., Ryan T.J. Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization. Circulation 1984, 70:788-792.
74. Schulman S., Bijsterveld N.R. Anticoagulants and their reversal. Transfus Med Rev 2007, 21:37-48.
75. Dehmer G.J., Lange R.A., Tate D.A., et al. Randomized trial of recombinant platelet factor 4 versus protamine for the reversal of heparin anticoagulation in humans. Circulation 1996, 94(9 Suppl):II347-II352.
76. Young G., Yonekawa K.E., Nakagawa P.A., Blain R.C., Lovejoy A.E., Nugent D.J. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagul Fibrinolysis 2007, 18:547-553.
77. Cherfan A., Arabi Y., Al Askar A., Al Shimemeri A. Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel. Pharmacotherapy 2007, 27:755-759.
78. Firozvi K., Deveras R.A., Kessler C.M. Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate. Am J Hematol 2006, 81:582-589.
79. Ng H.G., Koh L.P., Lee L.H. Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. Ann Hematol 2003, 82:257-258.
80. Johansson P.I. Off-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials. Vox Sang 2008, 95:1-7.
81. O'Connell K.A., Wood J.J., Wise R.P., Lozier J.N., Braun M.M. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006, 295:293-298.
82. Levi M., Levy J.H., Andersen H.F., Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010, 363:1791-1800.
83. Schick B.P., Gradowski J.F., San Antonio J.D., Martinez J. Novel design of peptides to reverse the anticoagulant activities of heparin and other glycosaminoglycans. Thromb Haemost 2001, 85:482-487.
84. Schick B.P., Maslow D., Moshinski A., San Antonio J.D. Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo. Blood 2004, 103:1356-1363.
85. Martins M.C., Curtin S.A., Freitas S.C., Salgueiro P., Ratner B.D., Barbosa M.A. Molecularly designed surfaces for blood deheparinization using an immobilized heparin-binding peptide. J Biomed Mater Res A 2009, 88:162-173.
86. Byun Y., Wang T., Kim J.S., Yang V.C. Optimization and assessment of the in vivo efficacy of a heparin removing bio-reactor using mathematical modeling. ASAIO J 1996, 42:M782-M787.
87. Zhang Y., Singh V.K., Yang V.C. Poly-L-lysine amplification of protamine immobilization and heparin adsorption. J Biomed Mater Res 1998, 42:182-187.
88. Donat F., Duret J.P., Santoni A., et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. ClinPharmacokinet 2002, 41(Suppl 2):1-9.
89. Lieu C., Shi J., Donat F., et al. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs. Clin Pharmacokinet 2002, 41(Suppl 2):19-26.
90. Harenberg J. Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb Haemost 2009, 102:811-815.
91. Faaij R.A., Burggraaf J., Schoemaker R., et al. A phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of subcutaneous SANORG 34006 in healthy male and female elderly volunteers. Thromb Haemost 1999, (Suppl). abstract 1547.
92. Faaij R.A., Burggraaf J., Schoemaker R.C., et al. A phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of SANORG 34006 in healthy young male volunteers. Thromb Haemost 1999, (Suppl). abstract 2709.
93. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. J Thromb Haemost 2004, 2:47-53. PERSIST Investigators.
94. Trellu M., Perez Y., Ortiz J., Cheng S., Paty I. Bioequipotency of idraparinux and biotinylated idraparinux after single dose in healthy subjects. J Thromb Haemost 2007, 5(Suppl 2). abstract P-T-678.
95. Gerotziafas G.T., Depasse F., Chakroun T., Samama M.M., Elalamy I. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thromb Haemost 2004, 91:531-537.
96. Lisman T., Bijsterveld N.R., Adelmeijer J., et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost 2003, 1:2368-2373.
97. Bijsterveld N.R., Vink R., van Aken B.E., et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004, 124:653-658.
98. Huvers F., Slappendel R., Benraad B., van Hellemondt G., van Kraaij M. Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid. Neth J Med 2005, 63:184-186.
99. Dao A., Tuan B., Carlson N. Reversal of a potent investigational anticoagulant: idraparinux with recombinant factor VIIa. Am J Med 2005, 118:1172-1173.
100. Bousser M.G., Bouthier J., et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008, 371:315-321. Amadeus Investigators.
101. Savi P., Herault J.P., Duchaussoy P., et al. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J Thromb Haemost 2008, 6:1697-1706.
102. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. J Thromb Haemost 2011, 9:92-99. Equinox Investigators.
103. Greinacher A., Eichler P., Lubenow N., Kwasny H., Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000, 96:846-851.
104. Tardy B., Lecompte T., Boelhen F., et al. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood 2006, 108:1492-1496.
105. Lubenow N., Eichler P., Lietz T., Greinacher A. Lepirudin in patients with heparin-induced thrombocytopenia-results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005, 3:2428-2436. Hit Investigators Group.
106. Hacquard M., de Maistre E., Lecompte T. Lepirudin: is the approved dosing schedule too high?. J Thromb Haemost 2005, 3:2593-2596.
107. Warkentin T.E., Greinacher A., Koster A., Lincoff A.M. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133(6 Suppl):340S-380S. American College of Chest Physicians.
108. Lewis B.E., Wallis D.E., Leya F., Hursting M.J., Kelton J.G. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003, 163:1849-1856. Argatroban-915 Investigators.
109. Lewis B.E., Wallis D.E., Berkowitz S.D., et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001, 103:1838-1843.
110. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 2002, 359:294-302. Direct Thrombin Inhibitor Trialists' Collaborative Group.
111. Schulman S., Kearon C., Kakkar A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352.
112. Ezekowitz M.D., Wallentin L., Connolly S.J., et al. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation 2010, 122:2246-2253.
113. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
114. Greinacher A., Warkentin T.E. The direct thrombin inhibitor hirudin. Thromb Haemost 2008, 99:819-829.
115. Stangier J., Rathgen K., Stahle H., Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010, 49:259-268.
116. Oh J.J., Akers W.S., Lewis D., Ramaiah C., Flynn J.D. Recombinant factor VIIa for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepirudin. Pharmacotherapy 2006, 26:569-577.
117. Malherbe S., Tsui B.C., Stobart K., Koller J. Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology 2004, 100:443-445.
118. Wolzt M., Levi M., Sarich T.C., et al. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thromb Haemost 2004, 91:1090-1096.
119. Perzborn E., Harwardt M. Recombinant factor VIIa partially reverses the effects of the Factor Xa inhibitor rivaroxaban on thrombin generation, but not the effects of thrombin inhibitors, in vitro. J Thromb Haemost 2007, 5(Suppl 2.). abstract P-W-640.
120. Elg M., Carlsson S., Gustafsson D. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 2001, 101:145-157.
121. Diehl K.H., Romisch J., Hein B., Jessel A., Ronneberger H., Paques E.P. Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models. Haemostasis 1995, 25:182-192.
122. Ibbotson S.H., Grant P.J., Kerry R., Findlay V.S., Prentice C.R. The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro. Thromb Haemost 1991, 65:64-66.
123. Bove C.M., Casey B., Marder V.J. DDAVP reduces bleeding during continued hirudin administration in the rabbit. Thromb Haemost 1996, 75:471-475.
124. Dickneite G., Nicolay U., Friesen H.J., Reers M. Development of an anti-bleeding agent for recombinant hirudin induced skin bleeding in the pig. Thromb Haemost 1998, 80:192-198.
125. Lassen M.R., Ageno W., Borris L.C., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008, 358:2776-2786.
126. Kakkar A.K., Brenner B., Dahl O.E., et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008, 372:31-39.
127. Eriksson B.I., Borris L.C., Friedman R.J., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008, 358:2765-2775.
128. Turpie A.G., Lassen M.R., Davidson B.L., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009, 373:1673-1680.
129. Bauersachs R., Berkowitz S.D., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510. EINSTEIN Investigators.
130. Patel M.R. Stroke prevention using the oral direct factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF). Circulation 2010, 122:A21839. ROCKET Investigators.
131. Lassen M.R., Raskob G.E., Gallus A., Pineo G., Chen D., Portman R.J. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009, 361:594-604.
132. Lassen M.R., Raskob G.E., Gallus A., et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010, 375:807-815.
133. Lassen M.R., Gallus A., Raskob G.E., et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010, 363:2487-2498.
134. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364:806-817.
135. Gruber A., Marzec U.M., Buetehorn U., Hanson S., Perzborn E. Potential of activated prothrombin complex concentrate and activated Factor VII to reverse the anticoagulant effects of rivaroxaban in primates. Blood 2008, 112. abstract 3825.
136. Perzborn E., Tinel H. FEIBA reverses the effects of a high dose of rivaroxaban in rats. Pathophysiol Haemost Thromb 2008, 36:A40. (abstract P061).
137. Perzborn E., Trabandt A., Selbach K., Tinel H. Prothrombin complex concentrate reverses the effects of high dose rivaroxaban in rats. J Thromb Haemost 2009, 7(Suppl 2). Abstract PP-MO-183.
138. Lu G., DeGuzman F., Lakhotia S., Hollenbach S.J., Phillips D.R., Sinha U. Recombinant antidote for reversal of anticoagulation by factor Xa inhibitors. Blood 2008, 112. abstract 983.
139. Lu G., Luan P., Hollenbach S., et al. Reconstructed recombinant factor Xa as an antidote to reverse anticoagulation by factor Xa inhibitors. J Thromb Haemost 2009, 7(Suppl 2). abstract OC-TH-107.